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Background: The present study aimed to illustrate differences in characteristics and percep-
tion of dyspnea between young atopic adults who have no history of asthma (never-asthmatics)
with or without asymptomatic airway hyperresponsiveness (AHR) and those who had childhood
asthma and consider themselves to be grown out of the disease (past-asthmatics).
Methods: Blood parameters, lung function and methacholine PC20 were measured in 88 never-
asthmatics and 24 past-asthmatics. A perception score of dyspnea at 20% fall in FEV1 (PS20) was
obtained by interpolation of the two last points on the perception (modified Borg scale)/fall in
FEV1 curve during methacholine challenge.
Results: Thirty-one of 88 never-asthmatics and eighteen of 24 past-asthmatics exhibited AHR
(PC20 was <8 mg/ml). Higher levels of specific IgE to house dust mite in past-asthmatics were
observed than never-asthmatics with and without AHR. Mean values of FEV1 and FEF25e75 (%
predicted) were significantly lower in past-asthmatics than never-asthmatics without AHR,
and the values in never-asthmatics with AHR were intermediate between never-asthmatics
without AHR and past-asthmatics. PC20 was not significantly different between past-asthmatics
and never-asthmatics with AHR. Of particular interest was that PS20 was significantly lower in
never-asthmatics with AHR compared with past-asthmatics.
Conclusion: Thepresentfindings suggest thepossibilities thatpresenceor absenceof past history
of outgrow of childhood asthma might be associated with airway narrowing, sensitization to
house dust mite and perception of dyspnea in young asymptomatic adults with atopy and AHR.
ª 2010 Elsevier Ltd. All rights reserved.6 6645 3790; fax: þ81 6 6646 6067.
ka-cu.ac.jp (T. Yoshikawa).
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Bronchial asthma is characterized by variable airflow
obstruction and airway hyperresponsiveness (AHR). Many
studies demonstrated that some of symptom-free individ-
uals, particularly atopic young adults in the absence of
a history of pediatric asthma, can also exhibit AHR to
various inhaled agents in similar to symptomatic patients
with asthma.1 They usually believe themselves not to have
any predisposition related to AHR and asthma. Epidemio-
logical surveys reported that 4e35% of asymptomatic
subjects have AHR in general population, even if they had
no attacks of wheezing.2,3 A follow-up study has identified
such asymptomatic AHR as one of predictive factors for
initiation of future symptomatic asthma.1
In a subset of children diagnosed with atopic asthma,
respiratory symptoms often remit around puberty.4,5
Epidemiological studies showed that approximately 50% of
adults who reported having asthma in childhood no longer
have respiratory symptoms.4 They often consider them-
selves to be grown out of their disease at the stage of young
adulthood.6 However, airway narrowing and AHR with mild
airway inflammation and structural changes is reported to
persist throughout childhood and adulthood even in the
absence of respiratory symptoms.6e12 And respiratory
symptoms relapse later in some of these asthmatics.4,5
Thus, this asymptomatic group is known to be high risk
for future onset of asthma, in similar to the asymptomatic
AHR described above. However, knowledge is limited
regarding similarities and differences in physiological and
immunological aspects, including spirometric measures,
AHR and allergic sensitization to a specific allergen,
between these two asymptomatic subject groups. In addi-
tion, it has not been investigated as to differences in
perception of dyspnea between these subject groups.
The first objective of the present study was to illustrate
differences in spirometric measures, airway responsiveness
to inhaled methacholine and allergy sensitization among
atopic young adults who were diagnosed with childhood
asthma at the school-ages and appeared to have remission
of their asthmatic symptoms in adolescence without use of
any asthma medication (referred to as past-asthmatics) and
age-matched atopic adults who do not have any past history
of wheeze symptoms (referred to as never-asthmatics) with
or without asymptomatic AHR. Second, the present study
aimed to examine the difference in perception of dyspnea
for bronchoconstriction after methacholine inhalation
among these subject groups. We hypothesized that the
spirometric variables, atopic parameters in blood and
perception of dyspnea by bronchoconstriction in never-
asthmatics with AHR might differ from those in age-
matched never-asthmatics without AHR and past-asth-
matics. Examination of such differences might help us to
characterize never-asthmatics with AHR and past-asth-
matics and to delineate the natural history of AHR and
asthma at the time of young adulthood.
Methods
Subjects were first recruited at random on the basis of a list
of university students and only never-smokers were askedto participate in the present study, including the blood
sampling and methacholine provocation testing. A clinical
history was taken and physical examination was performed
on all volunteers who agreed with the participation. Blood
samples were also collected from the same volunteers.
Then, only those who met at least one of the following
criteria were finally included in the present study;
1) current or past history of allergic diseases, such as hay
fever and atopic dermatitis diagnosed by specialists, 2) a
total serum IgE level of more than 250 IU/ml, or 3) one or
more specific IgE levels of more than 0.34 Ua/ml to house
dust mite (Dermatophagoides pteronyssinus), cat dander,
dog dander, or cedar pollen as determined by radioaller-
gosorbent test (RAST) using UniCAP IgE fluoroenzyme-
immunoassays (Sweden Diagnostics, Uppsala, Sweden).
Then, the study subjects were divided into two cate-
gories based on self-reported information; 1) those who do
not have any past history of wheeze symptoms (never-
asthmatics) and 2) those who had a history of asthma at
their school-ages diagnosed by pediatric specialists but had
no wheeze symptoms without use of any asthma medication
for at least 3 preceding years (past-asthmatics).13
Furthermore, never-asthmatics were divided into two
groups according to the airway response to methacholine
exposure; those with or without AHR.
A spirometer (Chestac-25F; Chest CO., Tokyo, Japan)
was used to obtain all spirometric measurements (FEV1,
FVC, FEV1/FVC and FEF25e75). The methacholine provoca-
tion test was performed for all subjects as recommended by
American thoracic Society (ATS) guidelines.14 Briefly,
subjects inhaled saline (baseline) or methacholine solution
(0.3e16 mg/ml) for 2 min by tidal breathing from a Devil-
biss 646 nebulizer (Devilbiss Co., Somerset, PA, USA)
operated with compressed air at 5 l/min. Spirometry was
performed about 30 s after inhalation and FEV1 was
measured. The measured values were plotted on a semi-
logarithmic graph and the provocative concentration of
methacholine causing a 20% fall in the FEV1 (PC20) was
calculated in noncumulative units by linear interpolation
between the last two points on the graph. If there was
a >20% fall in FEV1 to a methacholine concentration (PC20)
<8 mg/ml, the subject was categorized as having AHR. In
addition, immediately before each FEV1 measurement
during the methacholine challenge, perception of dyspnea
were evaluated according to a modified Borg scale from
0 (no symptom) to 10 (maximal bearable).15 Scores
between the fixed intervals were permitted (half an
interval, 0.5). A perception score at a 20% fall in FEV1 (PS20)
was obtained by interpolation of the two last points on the
perception/fall in FEV1 curve according to previous
studies.16,17 The PS20 was calculated only in the group of
never-asthmatics with asymptomatic AHR and that of past-
asthmatics who exhibited a significant fall (20%) in FEV1
because the PS20 values cannot be estimated by interpo-
lation unless more than 20% fall in FEV1 is produced by the
methacholine inhalation.
All statistical analyses were performed using SPSS for
Windows (SPSS Inc., Chicago, IL). Results are expressed as
median (range). Spirometric data, which were normally
distributed, are presented as mean  SD. Age, blood eosin-
ophils, serum IgE levels (specific to four common allergens
described above) and methacholine PC20 for three volunteer
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this returned a significant difference among groups, post-hoc
pairwise comparisons were performed by Dunn’s test.
Spirometric data, which were normally distributed, were
compared by one-way analysis of variance (ANOVA), with
post-hoc pairwise comparisons, where appropriate, per-
formed using Student-Newman-Keuls test. Serum total IgE
levels were transferred to logarithmic function to have nor-
mally skewed data during the analyses and three group
comparisons were performed in a manner similar to the
spirometric data. ManneWhitney U test was used for
comparison of PS20 and maximal fall in FEV1 during meth-
acholineprovocation test andBorg scores after control saline
solution between past-asthmatics and never-asthmatics
with AHRwho did not have a history of asthma. A P-value less
than 0.05 was considered as statistically significant.
The study was approved by our local Ethics Committee
and all subjects signed an informed consent form. And all
procedures were done according to the research ethics of
the Declaration of Helsinki.18
Results
Eighty-eight never-asthmatics (26 males, 62 females; aged
18e23 yrs) and 24past-asthmatics (7males, 17 females; aged
18e21 yrs) were recruited. The subject background is shown
in Table 1. Of the eighty-eight never-asthmatic volunteers,
31 (35.2%) exhibited significant AHR. Thirty-four of the 57
never-asthmaticswithout asymptomatic AHR, nineteen of 31
never-asthmatics with asymptomatic AHR and eighteen of 24
past-asthmatics had a history of allergic rhinitis. Age at onset
of asthma was from 0 to 7 years (median, 4 years) and
duration of the symptoms was 2e15 years (median, 9 years).
All past-asthmatics had used anti-asthma medications
(mostly bronchodilator) for different periods of time in
childhood. Past-asthmatics reported no symptom attributed
to asthma or did not need for anti-asthma medication for
periods of 3e13 years (median, 6 years).Table 1 Characteristics of subjects.
never-asthmatics
without AHR
(n Z 57)
Age [years] 19 (18e22)
Sex [M/F] 19/38
Allergic Rhinitis 34 (59.6%)
Onset of past asthma [years]
Duration of the past asthma [years]
Blood eosinophils [/mm3] 125.0 (0.0e548.7)
[%] 2.3 (0e8.4)
Log10 IgE (total, non-specific) [IU/mL] 2.4 (1.4e3.8)
Values are presented as median (range). Total IgE levels in serum we
Age of onset and duration of the past asthma is assessed [years] base
All subjects are life-long non-smokers.
Age, blood eosinophils, serum total IgE levels for three volunteer gro
never-asthmatics: subjects who do not have any past history of whee
past-asthmatics: subjects with a history of asthma in childhood and a
AHR: airway hyperresponsiveness.Blood eosinophil counts and percentages tend to vary
among three groups (eosinophil counts; P Z 0.072, eosin-
ophil percentages; P Z 0.082 by KruskaleWallis test,
respectively) (Table 1). These eosinophil parameters seem
to be lower in never-asthmatics without asymptomatic AHR
compared with the other two groups. All of the never-
asthmatics and past-asthmatics had a serum total IgE or
specific IgE above the upper limit of normal. There were no
significant differences in serum total IgE levels among three
volunteer groups. However, higher levels of specific IgE to
house dust mite were observed in the group of past-asth-
matics compared with the other two volunteer groups
(PZ 0.011 by KruskaleWallis test, PZ 0.014 vs. the never-
asthmatics without asymptomatic AHR, and P Z 0.006 vs.
those with asymptomatic AHR by post-hoc pairwise test,
respectively) (Fig. 1).
The mean values of baseline FEV1 and FEF25e75 (%pre-
dicted) were highest in never-asthmatics without asymp-
tomatic AHR, followed by those with asymptomatic AHR,
and lowest for the past-asthmatics (Fig. 2A and B). The
mean values of these spirometric parameters were signifi-
cantly lower in the past-asthmatic group compared with
the never-asthmatics without asymptomatic AHR (FEV1;
PZ 0.046 by one-way ANOVA, PZ 0.017 vs. those without
asymptomatic AHR by post-hoc pairwise test, FEF25e75;
PZ 0.047 by one-way ANOVA, PZ 0.017 vs. those without
asymptomatic AHR by post-hoc pairwise test, respectively).
The values of FVC and FEV1/FVC were not significantly
different among the three subject groups (data not shown).
Eighteen of 24 past-asthmatics (72%) exhibited an
increased response to methacholine (PC20 was <8 mg/ml)
(Fig. 3). The PC20 in the past-asthmatics varied between 0.7
and 16.0 mg/ml, with a median of 4.1 mg/ml (never-asth-
matics without asymptomatic AHR: 8.0e16.0 mg/ml;
median 16.0 mg/ml; never-asthmatics with asymptomatic
AHR: 1.8e8.0 mg/ml; median 5.1 mg/ml, respectively).
Although the PC20 showed a wide distribution in past-
asthmatics, the values were not significantly differentpast-asthmatics
with AHR
(n Z 31) (n Z 24) P-value
19 (18e23) 19 (18e21) 0.835
7/24 7/17
19 (61.3%) 18 (75.0%)
4 (0e7)
9 (2e15)
178.0 (0.0e548.4) 174.6 (19.5e709.8) 0.072
3.1 (0e10.1) 3.3 (0.6e13) 0.082
2.4 (1.1e3.5) 2.4 (1.5e3.8) 0.993
re presented as log10 IgE.
d on subject’s memory of symptom history.
ups were compared by KruskaleWallis test.
ze symptoms.
ppeared to have remission of the symptoms.
Figure 1 Serum levels of IgE specific to house dust mite in
young adult never-asthmatics without AHR, those with AHR,
and past-asthmatics. Horizontal bars represent median values
for the three groups. Higher levels of the specific IgE were
observed in the group of past-asthmatics compared with the
other two volunteer groups. IgE: immunoglobulin E, past-
asthmatics: subjects with a history of asthma in childhood and
appeared to have remission of the symptoms. never-asth-
matics: subjects who do not have any past history of wheeze
symptoms, AHR: airway hyperresponsiveness.
Figure 2 Mean values of FEV1 (A) and FEF25e75 (B) (%pre-
dicted) obtained from asymptomatic young adult never-asth-
maticswithoutAHR, thosewithAHR, andpast-asthmatics. These
spirometric parameters were significantly lower in the past-
asthmatic group compared with the never-asthmatics without
AHR. past-asthmatics: subjects with a history of asthma in
childhood and appeared to have remission of the symptoms.
never-asthmatics: subjects who do not have any past history of
wheeze symptoms, AHR: airway hyperresponsiveness.
Asymptomatic AHR vs. asthma remission 27between past-asthmatics (n Z 24) and never-asthmatics
with asymptomatic AHR.
Median (range) PS20 was 0.7 (0e4.6) in never-asthmatics
with asymptomatic AHR and 2.6 (0.4e6.9) in past-asthmatics
who had an increased airway response to methacholine
(nZ 18), respectively. Dyspnea by bronchoconstrictionwere
perceived significantly greater at 20% fall in FEV1 in the past-
asthmatics compared with never-asthmatics with asymp-
tomatic AHR (PZ 0.001) (Fig. 4). Maximal fall in FEV1 during
methacholine provocation test and Borg score after control
saline inhalation were similar between these two subject
groups (data not shown).
Discussion
A substantial body of evidence has accumulated regarding
pathophysiological basis of past-asthma after clinical
remission as well as that of asymptomatic AHR in never-
asthma. Both phenotypes are thought to be possible
predictive factors for future asthma, and some overlap is
likely to exist. The present study highlights the asymp-
tomatic AHR per se without past and current asthmatic
symptoms in young atopic adult population by comparing
between never-asthmatics with asymptomatic AHR and
past-asthmatics.
The present finding is consistent withmajority of previous
studies showing that past-asthmatics have occult impair-
ment in pulmonary function, such as that assessed by FEV1
and FEF25e75, comparedwith asymptomatic never-asthmaticcontrolswithout AHR.6,11,19,20 In contrast, spirometric values
in never-asthmatics with AHR seemed to be indistinguishable
from those in bothnever-asthmatic controlswithout AHRand
past-asthmatics, suggesting the possibilities that asymp-
tomatic AHR observed in the never-asthmatics might be
a mixed phenotype in terms of airway patency.
Previous studies of bronchial biopsies, bronchoalveolar
lavage (BAL) and induced sputum described pathophysio-
logical characteristics in airways of past-asthmatics and
those of never-asthmatics with AHR. Airway inflammation is
reported to persist even after remission of asthmatic
symptoms as observed in biopsy samples,21 BAL22 and
induced sputum,6 and is believed to one of major causes of
impaired pulmonary function and high risk for relapse in the
past-asthmatic adults. In the airways of subjects with
Figure 3 Methacholine PC20 measured in asymptomatic
young adult never-asthmatics with AHR and past-asthmatics
(n Z 24). Horizontal bars represent median values for the two
groups. PC20 was not significantly different between past-
asthmatics and never-asthmatics with AHR. AHR: airway
hyperresponsiveness.
28 T. Yoshikawa, H. Kanazawaasymptomatic AHR who never required any medication for
asthma, only mild inflammatory changes were shown to be
present in bronchial mucosa23 but to be scarce in inducedFigure 4 Perception of dyspnea at a 20% fall in FEV1 (PS20) in
asymptomatic young adult never-asthmatics with AHR and
past-asthmatics with more than 20% fall in FEV1 by meth-
acholine inhalation (nZ 18). Horizontal bars represent median
values for the two groups. Low PS20 values were observed in
never-asthmatics with asymptomatic AHR compared with past-
asthmatic subjects. AHR: airway hyperresponsiveness.sputum.24 To our best knowledge, however, airway
inflammatory parameters have not been directly compared
between never-asthmatics with AHR and past-asthmatics.
In addition to the present study, such approach using airway
secretions and biopsy samples will be needed in future
studies for understanding the pathophysiological similari-
ties and differences between the asymptomatic AHR in
never-asthmatics and past-asthmatics.
The airway responsiveness in past-asthmatics varies
largely. As previous studies, a subset of symptom-free past-
asthmatics showed mild AHR.5,11,25 In the present study,
75% of these subjects exhibited less than 8 mg/ml of the
PC20, and the overall airway responsiveness (n Z 24) was
similar to that in never-asthmatics with AHR. Conversely,
the present finding reveals evidence that, even if young
atopic adults had no history of asthmatic symptoms, some
of them have airway responsiveness comparable to the
past-asthmatics who have ever suffered from asthmatic
symptoms and received medication.
A significant higher level of serum IgE to house dust mite
in past-asthmatics is consistent with previous observa-
tion.26 In the present study, there were no significant
differences in the serum IgE levels to house dust mite
between never-asthmatics with and without AHR. The
finding indicates that the sensitization to the house dust
mite allergen is unlikely to participate in the development
of asymptomatic AHR in never-asthmatics. Furthermore,
a relationship between atopy to house dust mite and lung
growth in childhood is note of worthy. A previous study
demonstrated that growth of spirometric lung function was
impaired in children with AHR and/or atopy to house dust
mite or cat.27
Some previous studies compared dyspnea scores during
methacholine-induced bronchoconstriction as assessed by
PS20 in currently symptomatic patients with asthma with
those in young adults in clinical remission of asthma, and
those in subjects with asymptomatic AHR.16,28,29 In partic-
ular, Boulet et al. demonstrated that the values of PS20 are
significantly lower in asymptomatic AHR without any
asthma history compared with those in patients with long-
standing mild asthma.29 The PS20 values of the asymptom-
atic group in the study are likely to be similar with those
observed in the present study. To our best knowledge, the
present study first compared the perception of dyspnea
directly between never-asthmatics with AHR and past-
asthmatics in a similar way of these previous studies. Of
particular interest is that, despite common symptom-free
feature between never-asthmatics with AHR and past-
asthmatics, the PS20 in never-asthmatics with AHR is less
than that in past-asthmatics. The present finding suggests
the possibility that there might be different factors
involved in lack of asthmatic symptom between never-
asthmatics with AHR and past-asthmatics.
Characteristics observed in never-asthmatics with AHR
and past-asthmatics partly implicate outcomes of these
two asymptomatic young adult groups later in life. It is
plausible that past-asthmatics will have more severe
disease compared with never-asthmatics with AHR when
their symptoms relapse later in life because of preexisting
impairment of spirometric lung function during asymp-
tomatic phase. On the other hands, because spirometric
values of never-asthmatics with AHR are not significantly
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events, such as onset of asthma, cannot easily be predicted
by spirometric measure alone during the asymptomatic
phase in never-asthmatic individuals. Furthermore, never-
asthmatics with AHR might be less sensitive to airway nar-
rowing at asthmatic attacks, if any, because of their poor
perceptive recognition for airway narrowing. However,
a longitudinal study will be needed to compare directly
time course of spirometric measures and clinical outcomes
including rate of onset (never-asthmatics with AHR) or
relapse (past-asthmatics), disease severity and perception
of asthma attacks between never-asthmatics with AHR and
past-asthmatics.
There are some potential limitations of interpretation
of the present findings. First, we recruited a small
number of volunteers in the present study. It is necessary
to be repeated by other independent studies in order to
confirm the present findings. Second, statistical analysis
did not provide clear-cut difference in FEV1 and FEF25e75
between never-asthmatics with AHR and past-asthmatics.
It is possible that this is attributed to a small number of
subjects recruited and/or to the characteristics of the
never-asthmatic population which might includes
a variety of degree of the airway pathophysiological
changes from normal to nearly past-asthmatics. Third,
direct examination of the airway inflammatory parame-
ters in bronchial mucosa and airway secretions was not
performed. The present study was basically designed to
focus on differences in physiological and serological
aspects between past-asthmatics and never-asthmatics
with AHR. It will be necessary to compare these param-
eters in parallel with the observation similar as the
present study.
In conclusion, the present study describes differences in
airway narrowing, sensitization to house dust mite and
perception of dyspnea between past-asthmatics and never-
asthmatics with AHR in young atopic seemingly-asymp-
tomatic adults. The knowledge from the present study
might partly aid to develop effective measures specific for
each risk group which are required for prediction and
prevention of asthma.
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